Efficacy

Efficacy of Inqovi for Leukemia

Inqovi, which is a combination of decitabine and cedazuridine, is specifically indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. This oral hypomethylating agent has shown efficacy in clinical trials by improving the hematologic parameters and reducing the need for transfusions. The effectiveness of Inqovi is measured by the rate of complete remission (CR), duration of CR, and overall response rate (ORR), which includes CR and partial remission (PR).

Results from pivotal clinical trials demonstrate that Inqovi, when used in the appropriate patient population, can lead to a significant improvement in these outcomes. Patients treated with Inqovi have been observed to achieve higher rates of complete remission compared to those who received alternative treatments. The duration of these remissions also plays a critical role in the management of MDS, as longer remissions are associated with improved quality of life and potentially better long-term outcomes.

Efficacy of Daurismo for Leukemia

Daurismo (glasdegib) is approved for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years of age or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. Glasdegib, when used in combination with low-dose cytarabine (LDAC), has shown a significant improvement in overall survival compared to LDAC alone. The efficacy of Daurismo is primarily evaluated based on overall survival, event-free survival, and the rate of complete remission with full or partial hematologic recovery.

In clinical studies, patients treated with Daurismo in combination with LDAC had a median overall survival that was notably longer than that of patients who received LDAC alone. The combination therapy has been associated with a higher rate of complete remission, indicating that Daurismo can be an effective treatment option for older patients with AML or those who cannot tolerate more aggressive chemotherapy regimens. While the treatment does not cure AML, it can provide a significant survival benefit and improve the quality of life for patients with this challenging and often aggressive disease.